Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients
Background: Given the increased incidence of post-transplant diabetes and the high cardiovascular burden in transplant recipients, glycemic control and other cardiovascular risk factors such as blood pressure and cholesterol should be targeted aggressively. We aimed to analyze management of predomin...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 67 |
| creator | Tsomos, Effie Aleksic, Sandra Anaraki, Sara Zahedpour Japp, Emily Upadhyay, Laxmi Ajaimy, Maria Zonszein, Joel Akalin, Enver |
| description | Background: Given the increased incidence of post-transplant diabetes and the high cardiovascular burden in transplant recipients, glycemic control and other cardiovascular risk factors such as blood pressure and cholesterol should be targeted aggressively. We aimed to analyze management of predominantly Hispanic and non-Hispanic black kidney transplant recipients with type 2 diabetes (T2D) and new onset diabetes after transplant (NODAT).
Methods: We performed a retrospective chart review of all recipients of kidney transplant from June 01, 2012 until December 31, 2014 in a large university center. Recipients with type 1 diabetes or pancreas transplant were excluded. NODAT was defined by the ADA criteria.
Results: The study included 304 individuals. Fifty percent had T2D and another 36% developed NODAT during a follow-up of 37 (22-52) months. Individuals with T2D, compared to NODAT and non-DM, were more frequently treated with statins (76% vs. 65% vs. 39%, respectively, p |
| doi_str_mv | 10.2337/db18-448-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2099981218</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2099980812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c918-e9e368e239879fb7f831cb02fbf0ec592a6f0999b6aa152b994e2550258825e73</originalsourceid><addsrcrecordid>eNqFkc1KAzEURoMoWKsbnyDgThjNT2cmWcpoVaxYygjuQjKTYOo0qUkqzMpXN0X3chd3c777cTkAnGN0RSitr3uFWTGbsWJ5ACaYU15QUr8dgglCmBS45vUxOIlxjRCq8kzAdxu0TBvtEjQ-wFsrlU46Qul62MjQW_8lY7cbZIArGz_gXHbJhwitgxIug-79xjrp0jDCZ-t8sGmEr0FJBxv_7kOC3sAn2zs9wjZIF7dDhuFKd3Zrc2k8BUdGDlGf_e0paOd3bfNQLF7uH5ubRdHx_JHmmlZME8pZzY2qDaO4U4gYZZDuSk5kZRDnXFVS4pIozmealCUiJWOk1DWdgovfs9vgP3c6JrH2u-ByoyD7IMMEs_8plLlMXf5SXfAxBm3ENtiNDKPASOwtiL0FkS2IJf0B0x16sQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2099980812</pqid></control><display><type>article</type><title>Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Tsomos, Effie ; Aleksic, Sandra ; Anaraki, Sara Zahedpour ; Japp, Emily ; Upadhyay, Laxmi ; Ajaimy, Maria ; Zonszein, Joel ; Akalin, Enver</creator><creatorcontrib>Tsomos, Effie ; Aleksic, Sandra ; Anaraki, Sara Zahedpour ; Japp, Emily ; Upadhyay, Laxmi ; Ajaimy, Maria ; Zonszein, Joel ; Akalin, Enver</creatorcontrib><description>Background: Given the increased incidence of post-transplant diabetes and the high cardiovascular burden in transplant recipients, glycemic control and other cardiovascular risk factors such as blood pressure and cholesterol should be targeted aggressively. We aimed to analyze management of predominantly Hispanic and non-Hispanic black kidney transplant recipients with type 2 diabetes (T2D) and new onset diabetes after transplant (NODAT).
Methods: We performed a retrospective chart review of all recipients of kidney transplant from June 01, 2012 until December 31, 2014 in a large university center. Recipients with type 1 diabetes or pancreas transplant were excluded. NODAT was defined by the ADA criteria.
Results: The study included 304 individuals. Fifty percent had T2D and another 36% developed NODAT during a follow-up of 37 (22-52) months. Individuals with T2D, compared to NODAT and non-DM, were more frequently treated with statins (76% vs. 65% vs. 39%, respectively, p<0.001). At 6, 12, and 24 months posttransplant individuals with T2D, compared to NODAT, had higher levels of A1c (7.9 ± 1.8 vs. 6.5 ± 1.2%, 8.1 ± 1.8 vs. 6.6 ± 1.3%, 8.6 ± 2.1 vs. 6.6 ± 1.1%, respectively, p<0.0001 for all comparisons) and less frequently reached goal of <7% (33 vs. 80%, 26 vs. 71%, 14 vs. 79%, respectively, p<0.0001 for all comparisons). Most frequent glucose-lowering treatment in T2D was insulin (92%), followed by metformin (20%), DPP-4 inhibitors (19%) and sulfonylurea (11%), while NODAT was treated most frequently with diet only (43%), followed by metformin (20%) and DPP-4 inhibitors (20%).
Conclusions: While metabolic control was better in NODAT than T2D, both groups were predominantly treated with older glucose-lowering medications and had a significant number of individuals with suboptimal glucose and lipid management. Earlier and more aggressive treatment with cardio-protective and newer glucose-lowering agents is warranted in this high-risk population.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db18-448-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Blood pressure ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular system ; Cholesterol ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (insulin dependent) ; Diabetes mellitus (non-insulin dependent) ; Glucose ; Glucose monitoring ; Insulin ; Kidney transplantation ; Kidney transplants ; Kidneys ; Medical treatment ; Metformin ; Pancreas transplantation ; Risk factors ; Statins ; Sulfonylurea ; Transplants & implants</subject><ispartof>Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jul 1, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Tsomos, Effie</creatorcontrib><creatorcontrib>Aleksic, Sandra</creatorcontrib><creatorcontrib>Anaraki, Sara Zahedpour</creatorcontrib><creatorcontrib>Japp, Emily</creatorcontrib><creatorcontrib>Upadhyay, Laxmi</creatorcontrib><creatorcontrib>Ajaimy, Maria</creatorcontrib><creatorcontrib>Zonszein, Joel</creatorcontrib><creatorcontrib>Akalin, Enver</creatorcontrib><title>Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients</title><title>Diabetes (New York, N.Y.)</title><description>Background: Given the increased incidence of post-transplant diabetes and the high cardiovascular burden in transplant recipients, glycemic control and other cardiovascular risk factors such as blood pressure and cholesterol should be targeted aggressively. We aimed to analyze management of predominantly Hispanic and non-Hispanic black kidney transplant recipients with type 2 diabetes (T2D) and new onset diabetes after transplant (NODAT).
Methods: We performed a retrospective chart review of all recipients of kidney transplant from June 01, 2012 until December 31, 2014 in a large university center. Recipients with type 1 diabetes or pancreas transplant were excluded. NODAT was defined by the ADA criteria.
Results: The study included 304 individuals. Fifty percent had T2D and another 36% developed NODAT during a follow-up of 37 (22-52) months. Individuals with T2D, compared to NODAT and non-DM, were more frequently treated with statins (76% vs. 65% vs. 39%, respectively, p<0.001). At 6, 12, and 24 months posttransplant individuals with T2D, compared to NODAT, had higher levels of A1c (7.9 ± 1.8 vs. 6.5 ± 1.2%, 8.1 ± 1.8 vs. 6.6 ± 1.3%, 8.6 ± 2.1 vs. 6.6 ± 1.1%, respectively, p<0.0001 for all comparisons) and less frequently reached goal of <7% (33 vs. 80%, 26 vs. 71%, 14 vs. 79%, respectively, p<0.0001 for all comparisons). Most frequent glucose-lowering treatment in T2D was insulin (92%), followed by metformin (20%), DPP-4 inhibitors (19%) and sulfonylurea (11%), while NODAT was treated most frequently with diet only (43%), followed by metformin (20%) and DPP-4 inhibitors (20%).
Conclusions: While metabolic control was better in NODAT than T2D, both groups were predominantly treated with older glucose-lowering medications and had a significant number of individuals with suboptimal glucose and lipid management. Earlier and more aggressive treatment with cardio-protective and newer glucose-lowering agents is warranted in this high-risk population.</description><subject>Blood pressure</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular system</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Glucose</subject><subject>Glucose monitoring</subject><subject>Insulin</subject><subject>Kidney transplantation</subject><subject>Kidney transplants</subject><subject>Kidneys</subject><subject>Medical treatment</subject><subject>Metformin</subject><subject>Pancreas transplantation</subject><subject>Risk factors</subject><subject>Statins</subject><subject>Sulfonylurea</subject><subject>Transplants & implants</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkc1KAzEURoMoWKsbnyDgThjNT2cmWcpoVaxYygjuQjKTYOo0qUkqzMpXN0X3chd3c777cTkAnGN0RSitr3uFWTGbsWJ5ACaYU15QUr8dgglCmBS45vUxOIlxjRCq8kzAdxu0TBvtEjQ-wFsrlU46Qul62MjQW_8lY7cbZIArGz_gXHbJhwitgxIug-79xjrp0jDCZ-t8sGmEr0FJBxv_7kOC3sAn2zs9wjZIF7dDhuFKd3Zrc2k8BUdGDlGf_e0paOd3bfNQLF7uH5ubRdHx_JHmmlZME8pZzY2qDaO4U4gYZZDuSk5kZRDnXFVS4pIozmealCUiJWOk1DWdgovfs9vgP3c6JrH2u-ByoyD7IMMEs_8plLlMXf5SXfAxBm3ENtiNDKPASOwtiL0FkS2IJf0B0x16sQ</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Tsomos, Effie</creator><creator>Aleksic, Sandra</creator><creator>Anaraki, Sara Zahedpour</creator><creator>Japp, Emily</creator><creator>Upadhyay, Laxmi</creator><creator>Ajaimy, Maria</creator><creator>Zonszein, Joel</creator><creator>Akalin, Enver</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20180701</creationdate><title>Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients</title><author>Tsomos, Effie ; Aleksic, Sandra ; Anaraki, Sara Zahedpour ; Japp, Emily ; Upadhyay, Laxmi ; Ajaimy, Maria ; Zonszein, Joel ; Akalin, Enver</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c918-e9e368e239879fb7f831cb02fbf0ec592a6f0999b6aa152b994e2550258825e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Blood pressure</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular system</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Glucose</topic><topic>Glucose monitoring</topic><topic>Insulin</topic><topic>Kidney transplantation</topic><topic>Kidney transplants</topic><topic>Kidneys</topic><topic>Medical treatment</topic><topic>Metformin</topic><topic>Pancreas transplantation</topic><topic>Risk factors</topic><topic>Statins</topic><topic>Sulfonylurea</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsomos, Effie</creatorcontrib><creatorcontrib>Aleksic, Sandra</creatorcontrib><creatorcontrib>Anaraki, Sara Zahedpour</creatorcontrib><creatorcontrib>Japp, Emily</creatorcontrib><creatorcontrib>Upadhyay, Laxmi</creatorcontrib><creatorcontrib>Ajaimy, Maria</creatorcontrib><creatorcontrib>Zonszein, Joel</creatorcontrib><creatorcontrib>Akalin, Enver</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsomos, Effie</au><au>Aleksic, Sandra</au><au>Anaraki, Sara Zahedpour</au><au>Japp, Emily</au><au>Upadhyay, Laxmi</au><au>Ajaimy, Maria</au><au>Zonszein, Joel</au><au>Akalin, Enver</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2018-07-01</date><risdate>2018</risdate><volume>67</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Background: Given the increased incidence of post-transplant diabetes and the high cardiovascular burden in transplant recipients, glycemic control and other cardiovascular risk factors such as blood pressure and cholesterol should be targeted aggressively. We aimed to analyze management of predominantly Hispanic and non-Hispanic black kidney transplant recipients with type 2 diabetes (T2D) and new onset diabetes after transplant (NODAT).
Methods: We performed a retrospective chart review of all recipients of kidney transplant from June 01, 2012 until December 31, 2014 in a large university center. Recipients with type 1 diabetes or pancreas transplant were excluded. NODAT was defined by the ADA criteria.
Results: The study included 304 individuals. Fifty percent had T2D and another 36% developed NODAT during a follow-up of 37 (22-52) months. Individuals with T2D, compared to NODAT and non-DM, were more frequently treated with statins (76% vs. 65% vs. 39%, respectively, p<0.001). At 6, 12, and 24 months posttransplant individuals with T2D, compared to NODAT, had higher levels of A1c (7.9 ± 1.8 vs. 6.5 ± 1.2%, 8.1 ± 1.8 vs. 6.6 ± 1.3%, 8.6 ± 2.1 vs. 6.6 ± 1.1%, respectively, p<0.0001 for all comparisons) and less frequently reached goal of <7% (33 vs. 80%, 26 vs. 71%, 14 vs. 79%, respectively, p<0.0001 for all comparisons). Most frequent glucose-lowering treatment in T2D was insulin (92%), followed by metformin (20%), DPP-4 inhibitors (19%) and sulfonylurea (11%), while NODAT was treated most frequently with diet only (43%), followed by metformin (20%) and DPP-4 inhibitors (20%).
Conclusions: While metabolic control was better in NODAT than T2D, both groups were predominantly treated with older glucose-lowering medications and had a significant number of individuals with suboptimal glucose and lipid management. Earlier and more aggressive treatment with cardio-protective and newer glucose-lowering agents is warranted in this high-risk population.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db18-448-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2099981218 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Blood pressure Cardiovascular disease Cardiovascular diseases Cardiovascular system Cholesterol Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Glucose Glucose monitoring Insulin Kidney transplantation Kidney transplants Kidneys Medical treatment Metformin Pancreas transplantation Risk factors Statins Sulfonylurea Transplants & implants |
| title | Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T10%3A42%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20for%20Diabetes%20and%20Cardiovascular%20Risk%20Factors%20in%20a%20Predominantly%20Minority%20Urban%20Cohort%20of%20Kidney%20Transplant%20Recipients&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=Tsomos,%20Effie&rft.date=2018-07-01&rft.volume=67&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db18-448-P&rft_dat=%3Cproquest_cross%3E2099980812%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2099980812&rft_id=info:pmid/&rfr_iscdi=true |